Survivorship and the Challenge of "Late Effects"
As survival rates reach historic highs in 2026, the US medical community is grappling with the long-term health of survivors.
A seminal 2025 study revealed that over 70% of high-risk survivors suffer from moderate-to-severe hearing loss due to cisplatin chemotherapy. Other common "Late Effects" include growth failure, thyroid dysfunction, and a higher risk of secondary cancers. In response, 2026 has seen the standardization of Comprehensive Survivorship Programs at major US children's hospitals. These programs utilize "exposure-based screening," where a survivor's follow-up care is tailored specifically to the types of chemotherapy and radiation they received, focusing on early intervention for cardiac, pulmonary, and hearing issues to ensure a high quality of life after cancer.
